Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial

share with twitter share with LinkedIn share with facebook
09/24/2020 | 02:16pm EDT
FILE PHOTO: A syringe with a vaccine is seen ahead of trials by volunteers testing for the coronavirus disease (COVID-19), and taking part in the country's human clinical trial for potential vaccines at the Wits RHI Shandukani Research Centre in Joha

Pfizer's German development partner BioNTech on Thursday joined other leading COVID-19 vaccine developers in ruling out participation in British plans to test experimental inoculations by deliberately infecting trial volunteers.

"BioNTech's vaccine candidate is not part of this study," a spokeswoman said.

Britain is planning to host so-called "challenge trials", the Financial Times cited people involved in the project as saying. Britain said it was working with partners on the potential for human challenge trials without commenting on a specific plan.

AstraZeneca and Sanofi and Moderna, among the leading vaccine developers, have said their vaccine candidates were not involved in the programme.

U.S. biotech firm Inovio Pharmaceuticals also said it was not involved while Johnson & Johnson said it was evaluating the potential benefit of a human challenge trial but would not comment on the British plans.

The World Health Organisation was not involved in such studies, a spokesman said on Thursday.

In a paper https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf?ua=1 published in May, the WHO said challenge trials could be risky even if limited to young, healthy adults because too little is known about how COVID-19 progresses and there are no specific treatments apart from Gilead's remdesivir.

U.S.-based advocacy group 1Day Sooner, which is lining up volunteers and is lobbying for challenge trials, in a media briefing on Thursday said it did not have confirmation about which vaccines had been eyed for testing in Britain.

Leading vaccine makers have each recruited tens of thousands of volunteers in late-stage trials that rely on accidental infections to yield results on efficacy.

(Additional reporting by Trisha Roy and Sri Kalyani Manojna Maddipatla; editing by Thomas Seythal and Alexandra Hudson)


Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.98% 8112 Delayed Quote.4.42%
BIONTECH SE -2.19% 86.61 Delayed Quote.161.78%
GILEAD SCIENCES, INC. -2.09% 59.5 Delayed Quote.-6.45%
INOVIO PHARMACEUTICALS, INC. -4.29% 10.49 Delayed Quote.231.82%
MODERNA, INC. -1.62% 69.47 Delayed Quote.260.58%
PFIZER INC. -1.68% 37.575 Delayed Quote.-2.55%
PFIZER LIMITED 1.47% 5188.25 End-of-day quote.22.82%
SANOFI -0.05% 82.85 Real-time Quote.-7.45%
share with twitter share with LinkedIn share with facebook
All news about GILEAD SCIENCES, INC.
01:44pGILEAD SCIENCES : Completes Acquisition of Immunomedics, Inc.
AQ
01:44pLIGAND PHARMACEUTICALS INCORPORATED : Captisol Technology Plays Key Role in the ..
AQ
10/24To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
DJ
10/24GILEAD SCIENCES : Mexico will not follow FDA in approving Gilead's COVID-19 drug
RE
10/23Stocks mixed; COVID-19 vaccine trials to restart
RE
10/23GILEAD SCIENCES INC : Completion of Acquisition or Disposition of Assets, Other ..
AQ
10/23S&P, Nasdaq close higher as stimulus talks in spotlight
RE
10/23Intel, American Express fall; Mattel, Boston Beer rise
AQ
10/23ASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
DJ
10/23ASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
DJ
More news
Financials (USD)
Sales 2020 24 029 M - -
Net income 2020 2 246 M - -
Net Debt 2020 3 105 M - -
P/E ratio 2020 37,0x
Yield 2020 4,42%
Capitalization 76 214 M 76 214 M -
EV / Sales 2020 3,30x
EV / Sales 2021 3,24x
Nbr of Employees 11 800
Free-Float 99,6%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 78,08 $
Last Close Price 60,79 $
Spread / Highest target 72,7%
Spread / Average Target 28,4%
Spread / Lowest Target -6,23%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-6.45%76 214
REGENERON PHARMACEUTICALS54.42%61 014
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.59.09%37 775
BEIGENE, LTD.80.38%27 097
GENMAB A/S49.17%22 988